Although more pronounced during mood episodes, widespread cognitive deficits also persist after symptom remission for a significant proportion of individuals with bipolar disorder (BD). These cognitive difficulties limit recovery and are strongly associated with a wide range of functional goals such as employment and interpersonal relationships. This mounting evidence of the importance of cognitive functions now requires action if we are to improve recovery outcomes for the long-term. Cognitive Remediation (CR), originally developed to treat people with a diagnosis of schizophrenia, has recently emerged as a potential treatment option to promote functional recovery by targeting cognitive difficulties in people with BD. Numerous controlled trials have established the efficacy of CR paradigms for people with schizophrenia and these provide a basisfor CR programs to be tested in other mental health conditions also characterized by cognitive difficulties.
| HE TEROG ENEIT Y OF COG NITIVE D IFFICULTIE S IN PEOPLE WITH B DAdopting CR paradigms from schizophrenia appears reasonable for BD research when considering the similarities in the cognitive profiles across schizophrenia and BD. However, there are also differences between these two populations and appropriately adjusting treatment manuals could improve treatment outcomes. For example, whereas most patients with schizophrenia experience severe cognitive impairment across many cognitive domains, there are subgroups of BD patients presenting with discrete cognitive problems while others remain cognitively intact.Profile differences might result from differing developmental trajectories and illness progression among patient subgroups.Unlike in schizophrenia, where cognitive impairment is predominantly associated with neurodevelopmental factors, the longitudinal course of cognitive dysfunction for some people with BD seems to involve neurodevelopmental (eg, early-life premorbid deficits) and for others neuroprogressive (eg, effect of manic episodes) factors. 1 Thus, it is unclear whether we can just provide the same therapy paradigms developed for schizophrenia to people with BD or whether adaptations of CR paradigms are needed to account for the distinct characteristics of different BD subgroups.